Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Cantor Fitzgerald

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) was upgraded by stock analysts at Cantor Fitzgerald to a "strong-buy" rating in a report released on Wednesday,Zacks.com reports.

Several other equities analysts also recently weighed in on STOK. HC Wainwright cut their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday. Chardan Capital reissued a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $23.20.

Stoke Therapeutics Stock Performance

NASDAQ STOK opened at $8.99 on Wednesday. Stoke Therapeutics has a one year low of $5.35 and a one year high of $17.58. The stock has a 50-day moving average of $8.09 and a 200 day moving average of $10.01. The company has a market capitalization of $490.83 million, a price-to-earnings ratio of -4.28 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million for the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, equities analysts predict that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 10,382 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares of the company's stock, valued at approximately $554,550.54. This trade represents a 5.72% decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock valued at $143,332 over the last 90 days. 11.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. AlphaQuest LLC purchased a new position in shares of Stoke Therapeutics in the first quarter valued at approximately $72,000. Erste Asset Management GmbH acquired a new position in shares of Stoke Therapeutics in the 1st quarter valued at $2,670,000. Wellington Management Group LLP grew its position in Stoke Therapeutics by 0.9% in the 1st quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock valued at $904,000 after buying an additional 1,148 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in Stoke Therapeutics in the 1st quarter valued at $92,000. Finally, Russell Investments Group Ltd. purchased a new position in Stoke Therapeutics in the 1st quarter valued at $107,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.